Kuroda Keiji, Kitade Mari, Kumakiri Jun, Jinushi Makoto, Shinjo Azusa, Ozaki Rie, Ikemoto Yuko, Katoh Noriko, Takeda Satoru
Department of Obstetrics and Gynecology, Juntendo University Faculty of Medicine, Tokyo, Japan.
J Obstet Gynaecol Res. 2016 Feb;42(2):178-83. doi: 10.1111/jog.12862. Epub 2015 Nov 10.
The aim of this study was to assess the efficacy of a minimal ovarian stimulation involving combined clomiphene citrate (CC) and estradiol (E2) administration for poor responders with diminished ovarian reserve (DOR).
In this case-control study, we recruited 41 consecutive hypergonadotropic poor responders (69 cycles) who met Bologna-criteria and had experienced cancellation of oocyte retrieval. In 10 (20 cycles), 11 (21 cycles) and 20 patients (28 cycles) between 2012 and 2014, follicular development was induced using an E2 cycle, CC cycle and CC + E2 cycle, respectively. After confirmation of high follicle-stimulating hormone levels (15-40 mIU/ml) at menstrual day 3, DOR patients were treated with oral E2 of 1.0 mg/day, CC of 100 mg/day, or both CC and E2 continuously, until ovulation induction. Two days later, we transvaginally aspirated the follicles, performed in vitro fertilization, and cryopreserved the cleavage embryos. One warmed embryo was transferred into the uterus during the hormone replacement cycles.
For the E2, CC, and CC + E2 cycles, the median patient age was 41 years in all groups, and the serum anti-Müllerian hormone levels were 0.2 ± 0.3, 0.4 ± 0.4, and 0.2 ± 0.3 ng/mL, respectively (P = 0.258); follicular development failure rates were 50.0%, 19.0%, and 3.6%, respectively (P < 0.001); numbers of retrieved oocytes (/cycle) were 0.5 ± 0.6, 0.8 ± 0.7, and 1.2 ± 1.1, respectively (P = 0.033); and clinical pregnancy rates (/cycle) were 5.0%, 4.8%, and 10.7%, respectively (P = 0.725).
CC + E2 administration for the patients with DOR was effective with a lower cancellation rate of oocyte retrieval and a higher number of retrieved oocytes.
本研究旨在评估联合使用枸橼酸氯米芬(CC)和雌二醇(E2)进行最小化卵巢刺激对卵巢储备功能减退(DOR)的低反应者的疗效。
在这项病例对照研究中,我们连续招募了41名符合博洛尼亚标准且经历过取卵取消的高促性腺激素性低反应者(69个周期)。在2012年至2014年期间,分别有10名(20个周期)、11名(21个周期)和20名患者(28个周期),使用E2周期、CC周期和CC + E2周期诱导卵泡发育。在月经周期第3天确认卵泡刺激素水平升高(15 - 40 mIU/ml)后,DOR患者分别接受每日1.0 mg的口服E2、每日100 mg的CC或CC与E2联合持续治疗,直至诱导排卵。两天后,经阴道穿刺抽吸卵泡,进行体外受精,并冷冻保存分裂期胚胎。在激素替代周期中将一枚解冻胚胎移植到子宫内。
对于E2周期、CC周期和CC + E2周期,所有组患者的中位年龄均为41岁,血清抗苗勒管激素水平分别为0.2±0.3、0.4±0.4和0.2±0.3 ng/mL(P = 0.258);卵泡发育失败率分别为50.0%、19.0%和3.6%(P < 0.001);回收的卵母细胞数量(/周期)分别为0.5±0.6、0.8±0.7和1.2±1.1(P = 0.033);临床妊娠率(/周期)分别为5.0%、4.8%和10.7%(P = 0.725)。
对于DOR患者,CC + E2给药有效,取卵取消率较低且回收的卵母细胞数量较多。